2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Implications of remote monitoring Technology in Optimizing Traditional Self-Monitoring of blood glucose in adults with T2DM in primary care

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Self-monitoring of blood glucose (SMBG) has been shown to reduce hemoglobin A1C (HbA1C). Accordingly, guidelines recommend SMBG up to 4–10 times daily for adults with type 2 diabetes (T2DM) on insulin. For persons not on insulin, recommendations are equivocal. Newer technology-enabled blood glucose monitoring (BGM) devices can facilitate remote monitoring of glycemic data. New evidence generated by remote BGM may help to guide best practices for frequency and timing of finger-stick blood glucose (FSBG) monitoring in uncontrolled T2DM patients managed in primary care settings. This study aims to evaluate the impact of SMBG utility and frequency on glycemic outcomes using a novel BGM system which auto-transfers near real-time FSBG data to a cloud-based dashboard using cellular networks.

          Methods

          Secondary analysis of the intervention arm of a comparative non-randomized trial with propensity-matched chart controls. Adults with T2DM and HbA1C > 9% receiving care in five primary care practices in a healthcare system participated in a 3-month diabetes boot camp (DBC) using telemedicine and a novel BGM to support comprehensive diabetes care management. The primary independent variable was frequency of FSBG. Secondary outcomes included frequency of FSBG by insulin status, distribution of FSBG checks by time of day, and hypoglycemia rates.

          Results

          48,111 FSBGs were transmitted by 359 DBC completers. Participants performed 1.5 FSBG checks/day; with 1.6 checks/day for those on basal/bolus insulin. Higher FSBG frequency was associated with greater improvement in HbA1C independent of insulin treatment status ( p = 0.0003). FSBG frequency was higher in patients treated with insulin ( p = 0.003). FSBG checks were most common pre-breakfast and post-dinner. Hypoglycemia was rare (1.2% < 70 mg/dL).

          Conclusions

          Adults with uncontrolled T2DM achieved significant HbA1C improvement performing just 1.5 FSBGs daily during a technology-enabled diabetes care intervention. Among the 40% taking insulin, this improvement was achieved with a lower FSBG frequency than guidelines recommend. For those not on insulin, despite a lower frequency of FSBG, they achieved a greater reduction in A1C compared to patients on insulin. Low frequency FSBG monitoring pre-breakfast and post-dinner can potentially support optimization of glycemic control regardless of insulin status in the primary care setting.

          Trial registration

          Trial registration number : NCT02925312 (10/19/2016).

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12902-021-00884-6.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

          Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

            To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c). In a randomized, open-label, parallel, 24-week multicenter trial, 756 overweight men and women with inadequate glycemic control (HbA(1c) >7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Diabetes 2030: Insights from Yesterday, Today, and Future Trends

              Abstract To forecast future trends in diabetes prevalence, morbidity, and costs in the United States, the Institute for Alternative Futures has updated its diabetes forecasting model and extended its projections to 2030 for the nation, all states, and several metropolitan areas. This paper describes the methodology and data sources for these diabetes forecasts and discusses key implications. In short, diabetes will remain a major health crisis in America, in spite of medical advances and prevention efforts. The prevalence of diabetes (type 2 diabetes and type 1 diabetes) will increase by 54% to more than 54.9 million Americans between 2015 and 2030; annual deaths attributed to diabetes will climb by 38% to 385,800; and total annual medical and societal costs related to diabetes will increase 53% to more than $622 billion by 2030. Improvements in management reducing the annual incidence of morbidities and premature deaths related to diabetes over this time period will result in diabetes patients living longer, but requiring many years of comprehensive management of multiple chronic diseases, resulting in dramatically increased costs. Aggressive population health measures, including increased availability of diabetes prevention programs, could help millions of adults prevent or delay the progression to type 2 diabetes, thereby helping turn around these dire projections.
                Bookmark

                Author and article information

                Contributors
                arm243@georgetown.edu
                Torotobon.david@mayo.edu
                kgann@gobio.com
                Carine.M.Nassar@MedStar.net
                Gretchen.A.Youssef@Medstar.net
                Michelle.F.Magee@Medstar.net
                Journal
                BMC Endocr Disord
                BMC Endocr Disord
                BMC Endocrine Disorders
                BioMed Central (London )
                1472-6823
                10 November 2021
                10 November 2021
                2021
                : 21
                : 222
                Affiliations
                [1 ]GRID grid.411663.7, ISNI 0000 0000 8937 0972, Department of Medicine, , MedStar Georgetown University Hospital, ; 3800 Reservoir Rd, Washington, DC, 20007 USA
                [2 ]GRID grid.415232.3, ISNI 0000 0004 0391 7375, MedStar Diabetes Institute, ; 100 Irving Street, NW # 4114, Washington, DC, 20010 USA
                [3 ]GRID grid.66875.3a, ISNI 0000 0004 0459 167X, Mayo Clinic, Division of Endocrinology, ; 200 1st Street NW, Rochester, MN 55905 USA
                [4 ]GRID grid.470466.7, BioTelemetry, ; 1000 Cedar Hollow Road, Suite 102, Malvern, PA 19355 USA
                [5 ]GRID grid.415232.3, ISNI 0000 0004 0391 7375, MedStar Health Research Institute, ; 6525 Belcrest Road, Suite 700, Hyattsville, MD 20782 USA
                [6 ]GRID grid.213910.8, ISNI 0000 0001 1955 1644, Georgetown University, School of Medicine, ; 3900 Reservoir Rd NW, Washington, DC, 20007 USA
                Author information
                http://orcid.org/0000-0003-1910-4144
                Article
                884
                10.1186/s12902-021-00884-6
                8582211
                34758807
                492c2d2f-fc32-45c9-90cd-d41e53113885
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 4 March 2021
                : 22 October 2021
                Funding
                Funded by: Medstar Health
                Funded by: BioTel
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2021

                Endocrinology & Diabetes
                blood glucose meter,self-monitoring of blood glucose,diabetes care management,remote glucose monitoring

                Comments

                Comment on this article